Advanced Search
Submit Manuscript Volume 32, No 6, Jun 2022
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 32 Issue 6, June 2022: 505-506
Amplifying natural antitumor immunity for personalized immunotherapy
Laura K. Donovan1,* , Michael D. Taylor2
1Great Ormond Street Institute of Child Health, University College London, London, UKT-cells engineered with T-cell receptors (TCR-T), chimeric antigen receptor (CAR) T-cells, and neoantigen vaccines have each demonstrated therapeutic success in clinical trials, but many of these therapies can only benefit a small group of patient types owing to the restriction of certain tumor-associated antigens; personalized immunotherapy customizes cancer treatments to each patient, achieving greater responses without damaging normal tissues. In a recent Cell Research paper, He et al. show that TCR-T cells engineered with TCRs from naturally occurring tumor antigen-specific (Tas) T-cells are an effective therapy against non-small cell lung carcinoma, and a promising agent for future immunotherapies.
https://doi.org/10.1038/s41422-022-00649-3